Geron reports record quarterly revenue of $57.5 million and raises its 2026 RYTELO revenue guidance to $230M-$240M as the company accelerates its expansion into community oncology treatment settings.
Geron raised 2026 RYTELO revenue guidance to $230M-$240M, reported record quarterly revenue, and expanding community adoption, indicating strong commercial momentum.
Geron Corporation has lifted its 2026 revenue guidance for its RYTELO therapy to a range of $230 million to $240 million, citing record quarterly sales of $57.5 million. The company is successfully shifting its commercial focus toward community oncology practices, which represent 80% of the lower-risk MDS market, while maintaining a robust cash position of over $300 million.
The updated guidance is driven by record quarterly revenue of $57.5 million and successful expansion into community oncology practices, which represent the majority of the lower-risk MDS market.